Hims & Hers Health: GLP-1 Is Not The Only Tailwind In This Growth Story

Nastasic/E+ via Getty Images Introduction & Investment Thesis I last wrote about Hims & Hers Health (NYSE:HIMS) in May, where I initiated a "strong buy" rating based on my thesis that the stock should see significant upside as it focuses on growing its personalized solutions in existing and new specialties, with a goal of reaching $100M+ in revenue for each of its new specialties by 2025. Since then, the stock climbed over 100% to a peak price of $25 in June; however, it has since come back down to its curr ...